Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

"Next week in Dubai" We’ll be hosting a private investor discussion on "why aging is becoming the next major drug category". The thesis is simple. Nature has already demonstrated that aging can be dramatically slowed. Some mammals (naked mole rats, some species of bats and whales) show little to no increase in mortality with age and live many times longer than closely related species. These are not curiosities — they are biological proof that the *rate of aging is adjustable*. What has been missing is a way to turn that insight into medicine. "Ozempic and Wegovy showed what happens when a fundamental biological process is reframed into a druggable target." Metabolism moved from lifestyle and wellness into one of the largest therapeutic categories in pharma. Aging is next. At Gero, we’ve followed the long path from first-principles science to drug discovery. Our work applies physics to model aging as a system-level process and to identify therapeutic interventions. This approach has since been formalized as Gerophysics, a new scientific field recognized by *Nature*. That foundation has translated into practice: publishing foundational scientific work, building AI-driven drug discovery platforms, demonstrating systemic rejuvenation in mammals, and establishing commercial partnerships with global pharmaceutical leaders including Pfizer and Roche. I’m looking forward to sharing what we’ve learned. "What we’ll discuss:" * What we now understand about aging — and what remains impossible (for now) * Why aging is moving beyond wellness into a druggable, multi-disease target * Which longevity approaches are unlikely to scale — and which can support real therapeutics * How physics-based models and AI make organism-level aging measurable and predictable * What this shift implies for pharma pipelines, investment strategy, and long-term value creation A central theme: "for the first time, currently living generations may realistically remain healthy long enough to experience a future that was previously out of reach" — a structural shift with implications far beyond healthcare. This is a "private session for investors and pharma executives" during World Health Expo week. If you’ll be in Dubai on "February 11" and this is relevant to your work, the link is in the comments. If you know someone for whom this discussion might be relevant, I’d appreciate you forwarding it to them. https://luma.com/h7jxhtaf

Don’t be stressed about your health, it’s speeds up aging: https://www.sciencedirect.com/science/article/abs/pii/S0306453025004275?via%3Dihub

Exactly! Invest in longevity and maybe you won’t die early

Longevity InTime maybe slow and have not so many breaking news, but we survived Here are the ones who collapsed, while we were slowing moving forward: https://www.linkedin.com/posts/niko-hems_forward-health-raised-660m-shut-down-activity-7424006193226096640-B_Vw?utm_source=share&utm_medium=member_ios&rcm=ACoAAATQlrMBgDUjysfj7JNUvDWjX_P-FQErukw The winners are not the ones who started first, but the ones who didn’t went off the track …

The Chinese startup Gestala, based in Chengdu, plans to use focused ultrasound initially to stimulate the brain and, potentially, to read its state. Ultrasound has long been used in medicine for diagnostics, but under certain parameters, it can not only visualize tissue but also act on it. Focused ultrasound can either destroy pathological structures or gently modulate neuronal activity without surgery. Such methods have already been approved for the treatment of Parkinson's disease, uterine fibroids, and certain tumors. Gestala's first clinical application will be the treatment of chronic pain. Research shows that stimulation of the anterior cingulate cortex, a brain region associated with the emotional perception of pain, can reduce pain for up to a week. The first version of the device will be stationary and used in clinics. The second version will be a wearable helmet that patients can use at home under a doctor's supervision. The company's future goals include depression, other mental disorders, stroke rehabilitation, Alzheimer's disease, and sleep disorders. Unlike implantable interfaces like Neuralink, which read the electrical activity of neurons, the ultrasound approach relies on measuring changes in blood flow in the brain. This is an indirect but potentially more widespread method of monitoring, as it isn't limited to a single area, such as the motor cortex. Gestala ultimately wants to create a closed-loop system: the device will identify pathological brain conditions, such as those associated with pain or depression, and immediately direct stimulation to the desired area. The founders emphasize that this isn't about enhancing cognitive abilities, but about restoring and normalizing brain function. However, experts note significant technical limitations. The skull significantly distorts and weakens ultrasound signals, and to date, accurate ultrasound readings of neural activity in humans have only been possible with special "windows" in the skull or implants. Furthermore, blood flow changes more slowly than the electrical activity of neurons, making this technology less suitable for tasks requiring high temporal precision, such as speech decoding. https://www.gestala.com/manifesto